ID - 825
RESULTS FROM VERIFY, A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RUSFERTIDE FOR THE TREATMENT OF POLYCYTHEMIA VERA
A Yacouba, AT Kuykendallb, N Pemmarajuc, K Pettitd, J Shatzele, A Lucchesif, V García-Guitérrezg, S Khannah, A Molinah, A Bankari
a University of Kansas Cancer Center, Kansas City, United States
b Moffitt Cancer Center, Tampa, United States
c MD Anderson Cancer Center, Houston, United States
d University of Michigan, Ann Arbor, United States
e Oregon Health & Science University, Portland, United States
f IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
g Hospital Universitario Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcalá, Madrid, Spain
h Protagonist Therapeutics, Inc., Newark, United States
i Princess Margaret Cancer Centre, Toronto, Canada
Ver más
